Article Information
History
- November 8, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jeffrey M. Adelglass1,
- Paul Bradley2,
- Miranda R. Cai3,
- Gordon Chau3,
- Raj Kalkeri3,
- Shane Cloney-Clark3,
- Mingzhu Zhu3,
- Zhaohui Cai3,
- Mark Eickhoff3,
- Joyce S. Plested3,
- Raburn M. Mallory3 and
- Lisa M. Dunkle3,*
- 1Research Your Health, 6020 West Parker Road, Suite 430, Plano, Texas, 75093, USA
- 2Meridian Clinical Research, 340 Eisenhower Drive, Ste 1500, Savannah, GA 31406
- 3Novavax, Inc., 700 Quince Orchard Road, Gaithersburg, Maryland, 20878, USA
- ↵*Corresponding author:
Lisa M. Dunkle, 700 Quince Orchard Road Gaithersburg, Maryland, 20878, USA LDunkle{at}novavax.com
Posted November 08, 2024.
Adjuvant Recombinant SARS-CoV-2 Spike Protein Vaccine Immunogenicity After Prior mRNA Vaccine Doses
